Bortlee 2 Lyophilized Injection
Generic Name – Bortezomib
Drug Class – Antineoplastic agent
Bortezomib is a proteasome inhibitor, approved by FDA for the treatment of refractory multiple myelomas and mantle cell lymphomas. It acts by inhibiting 26-S proteosome complex which regulates protein degradation. Blocking this proteosome complex disrupts various cell signaling pathways leading to cell cycle arrest, inhibition of angiogenesis and apoptosis. It also increases sensitivity of cancer cells to traditional anticancer agents (e.g., gemcitabine, cisplatin, paclitaxel, irinotecan, and radiation).
Dosage and Administration
- Recommended dose in Previously Untreated Multiple Myeloma: 1.3 mg/m2 administered as a 3-5 second bolus intravenous injection in combination with oral melphalan and oral prednisone for nine 6-week treatment cycles
- Recommended dose in Relapsed Multiple Myeloma and Mantle Cell Lymphoma: 1.3 mg/m2 administered as a 3 to 5 second bolus intravenous injection twice weekly for 2 weeks followed by a 10-day rest period
- Dose may be adjusted to manage adverse events that occur during treatment
Dosage Form and Strength
- Supplied as a single use sterile lyophilized powder for intravenous infusion<
- Available as 2mg vial for injection